Youjia-Bio Tongee-Medical Nucleic-Acid-Drug Partnership Targets Diabetes
Youjia Biomedical Technology and Hangzhou Tongee Medical Technology Co., Ltd officially signed a strategic cooperation...
Fosun-Pharma FXS0887 ATR-Inhibitor Gets NMPA Phase 1 Nod
Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that its FXS0887 tablet has...
TransThera Tinengotinib Cholangiocarcinoma Priority Review China
TransThera Sciences (Nanjing) Inc. (HKG: 2617) announces that Tinengotinib tablets have been included in the...
Bio-Sincerity UCAS R&D Center Pharma Synthesis
Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. (SHE: 301096) announced the signing of a cooperation agreement with...
Sino-Biopharm TQF3250 GLP-1 Capsule Wins FDA Clinical Approval for Weight Loss
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a core subsidiary of Sino Biopharmaceutical Limited...
Gene-Mink CAR-NK BCMA Therapy Wins China Approval for Multiple Myeloma
Beijing Gene Mink Biotechnology announced that its self-developed QM103 Cell Injection, a BCMA‑targeted CAR‑NK cell...
CSPC SYH2056 FDA Approval Targets Depression with 5-HT2A Agonist
CSPC Pharmaceutical Group Limited (HKG: 1093) announced that SYH2056 tablets, a Category 1 chemical drug, has...
Antengene XPOVIO sNDA Hong-Kong Approval Expands MM DLBCL Indications
Antengene Corporation Limited (HKG: 6996) announced that Hong Kong’s Department of Health approved two supplementary...
Duality DB-1324 ADC FDA IND Approval Advances GSK Partnership
Duality Biotherapeutics, Inc. (HKG: 9606) announced that its Investigational New Drug (IND) application for DB-1324,...
NHSA Guangzhou Drug-List Conference Releases 2025 Medical Insurance Formulary
The National Healthcare Security Administration (NHSA) announced it will host the 2025 Innovative Drugs High-Quality...
Simcere deuremidevir RSV Licensing Deal Targets China Breakthrough
Simcere Pharmaceutical Group Limited (HKG: 2096) and Vigonvita Life Sciences Co., Ltd. (HKG: 2630) entered...
Henlius Fovinaciclib CDK4-6 Breast-Cancer China Commercialization
Henlius Biotech (HKG: 2696) announced a collaboration with Avanc Pharmaceutical Co., Ltd. to advance the...
Hengrui Remimazolam ICU Sedation NMPA Application Accepted
Jiangsu Hengrui Pharmaceutical Co., Ltd (SHA: 600276, HKG: 1276) announced that China’s National Medical Products...
Novo Nordisk CagriSema Pediatric Obesity Trial to Enroll 460 Children
Novo Nordisk (NYSE: NVO) is planning to test its experimental obesity drug CagriSema in overweight...
Antengene ATG-022 CLDN18.2 ADC Gets China Nod for Keytruda Combo in Gastric Cancer
Antengene Corporation Limited (HKG: 6996) announced that China’s National Medical Products Administration (NMPA) has approved...
MSD MK-2214 Fast Track Alzheimer Data Positive
Merck Sharp & Dohme Inc. (MSD, NYSE: MRK) released first‑in‑human data for MK-2214 and MK-1167 in...
China Drug-Price Registration System Launches with First Batch of 10 Products
China’s Drug Price Registration System officially launched today with the first batch of 10 drug...
3SBio HK$3.1B Placement Funds R&D Pipeline for 705, 706, 008
3SBio Inc. (HKG: 1530) conditionally agreed to place 105,169,500 shares at HK$29.62 per share, raising...
Generate GB-0895 Asthma Phase III Trials to Enroll 1,600 Patients
Generate: Biomedicines today announced plans to initiate two global Phase III clinical trials (SOLAIRIA-1 and...
Henlius HLX14 Denosumab Biosimilar NDA Accepted by China CDE
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that the National Medical Products Administration’s Center for...